Small‐Molecule‐Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
Open accessAbstract
Androgen receptor (AR)‐dependent transcription is a major driver of prostate tumor cell proliferation. Consequently, it is the target of several antitumor chemotherapeutic agents, including the AR antagonist MDV3100/enzalutamide. Recent studies have shown that a single AR mutation (F876L) converts MDV3100 action from an antagonist to an agonist. Here we describe the generation of a novel class of selective androgen receptor degraders (SARDs) to address this resistance mechanism. Molecules containing hydrophobic degrons linked to small‐molecule AR ligands induce AR degradation, reduce expression of AR target genes and inhibit proliferation in androgen‐dependent prostate cancer cell lines. These results suggest that selective AR degradation may be an effective therapeutic prostate tumor strategy in the context of AR mutations that confer resistance to second‐generation AR antagonists.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Molecular chaperones Hsp70 and Hsp90 can recruit the co-chaperone E3 ligase CHIP, leading to ubiquitination and degradation of chaperone-bound client proteins.
“However, molecular chaperones Hsp70 and Hsp90 can also recruit the co-chaperone E3 ligase CHIP (C-terminus of Hsp70 interacting protein), which leads to ubiquitination and degradation of the chaperone-bound client proteins [56–59].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856 · see citing works
HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein Analysis
Los, G. V., Encell, L. P., McDougall, M. G., Hartzell, D., Karassina, N., Zimprich, C., Wood, M. G., Learish, R., Ohana, R. F., Urh, M., et al. (2008) · ACS Chemical Biology · doi:10.1021/cb800025k · Cited by 2,527 · see citing works
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · see citing works
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · see citing works
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780 · see citing works
Strategies for silencing human disease using RNA interference
Kim, D. H., & Rossi, J. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2006 · Cited by 1,078 · see citing works
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903 · see citing works
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 760 · see citing works
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 663 · see citing works
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635 · see citing works
Self-citationKorpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0142 · Cited by 559 · see citing works
Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M. A., Mandal, A., Deshaies, R. J., Sakamoto, K. M., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 502 · see citing works
Self-citationSmall-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., & Crews, C. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.597 · Cited by 429 · see citing works
Self-citationFlutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405 · see citing works
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397 · see citing works
Dillard, P., Lin, M., & Khan, S. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.013 · Cited by 225 · see citing works
Small, E. J., & Carroll, P. R. (1994) · Urology · doi:10.1016/0090-4295(94)90092-2 · Cited by 174 · see citing works
Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One
Corson, T. W., Aberle, N. S., & Crews, C. M. (2008) · ACS Chemical Biology · doi:10.1021/cb8001792 · Cited by 166 · see citing works
Self-citationBuckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 153 · see citing works
Self-citationTargeting the Undruggable Proteome: The Small Molecules of My Dreams
Crews, C. M. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.011 · Cited by 147 · see citing works
Self-citationInhibitor Mediated Protein Degradation
Long, M. J. C., Gollapalli, D. R., & Hedstrom, L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.04.008 · Cited by 136 · see citing works
Castration-resistant prostate cancer: Adaptive responses in the androgen axis
Egan, A., Dong, Y., Zhang, H., Qi, Y., Balk, S. P., & Sartor, O. A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.011 · Cited by 125 · see citing works
p23, a simple protein with complex activities
Felts, S. J., & Toft, D. O. (2003) · Cell Stress and Chaperones · doi:10.1379/1466-1268(2003)008 · Cited by 116 · see citing works
Identification of Hydrophobic Tags for the Degradation of Stabilized Proteins
Tae, H. S., Sundberg, T. B., Neklesa, T. K., Noblin, D. J., Gustafson, J. L., Roth, A. G., Raina, K., & Crews, C. M. (2012) · ChemBioChem · doi:10.1002/cbic.201100793 · Cited by 108 · see citing works
Self-citationKim, H. R., Kang, H. S., & Kim, H. D. (1999) · IUBMB Life · doi:10.1080/713803536 · Cited by 107 · see citing works
Teutsch, G., Goubet, F., Battmann, T., Bonfils, A., Bouchoux, F., Cerede, E., Gofflo, D., Gaillard-Kelly, M., & Philibert, D. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90257-7 · Cited by 107 · see citing works
An evaluation of bicalutamide in the treatment of prostate cancer
Schellhammer, P. F. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.9.1313 · Cited by 100 · see citing works
Molecular basis for the antiandrogen withdrawal syndrome
Miyamoto, H., Rahman, M. M., & Chang, C. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10757 · Cited by 81 · see citing works
Ishizaki, F., Nishiyama, T., Kawasaki, T., Miyashiro, Y., Hara, N., Takizawa, I., Naito, M., & Takahashi, K. (2013) · Scientific Reports · doi:10.1038/srep01528 · Cited by 78 · see citing works
Croxtall, J. D., & McKeage, K. (2011) · Drugs · doi:10.2165/11204810-000000000-00000 · Cited by 72 · see citing works
A Bidirectional System for the Dynamic Small Molecule Control of Intracellular Fusion Proteins
Neklesa, T. K., Noblin, D. J., Kuzin, A., Lew, S., Seetharaman, J., Acton, T., Kornhaber, G. J., Xiao, R., Montelione, G. T., Tong, L., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400569k · Cited by 52 · see citing works
Self-citationBuckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie · doi:10.1002/ange.201307761 · Cited by 11 · see citing works
Self-citationA Dual Small‐Molecule Rheostat for Precise Control of Protein Concentration in Mammalian Cells
Lin, Y., & Pratt, M. R. (2014) · ChemBioChem · doi:10.1002/cbic.201400006 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 30
- [1]Lin YH Pratt MR Chembiochem 2014 15 805 809 24615791 PMC4038124
- [2]Crews CM Chem. Biol 2010 17 551 555 20609404 PMC2925121
- [3]Balbas MD Evans MJ Hosfield DJ Wongvipat J Arora VK Watson PA Chen Y Greene GL Shen Y Sawyers CL Elife 2013 2 e00499 23580326 PMC3622181
- [4]Kim DH Rossi JJ Nat Rev Genet 2007 8 173 184 17304245
- [5]Davidson BL McCray PB Nat Rev Genet 2011 12 329 340 21499294 PMC7097665
- [6]Corson TW Aberle N Crews CM ACS Chem. Biol 2008 3 677 692 19112665 PMC2925120
- [7]Schneekloth JS Fonseca FN Koldobskiy M Mandal A Deshaies R Sakamoto K Crews CM J. Am. Chem. Soc 2004 126 3748 54 15038727
- [8]Schneekloth AR Pucheault M Tae HS Crews CM Bioorg Med Chem Lett 2008 18 5904 5908 18752944 PMC3175619
- [9]Buckley DL Crews CM Angew. Chem. Int. Ed. Engl 2014 53 2312 30 24459094 PMC4348030
- [10]Neklesa TK Tae HS Schneekloth AR Stulberg MJ Corson TW Sundberg TB Raina K a Holley S Crews CM Nat. Chem. Biol 2011 7 538 43 21725302 PMC3139752
- [11]Tae HS Sundberg TB Neklesa TK Noblin DJ Gustafson JL Roth AG Raina K Crews CM Chembiochem 2012 13 538 541 22271667 PMC3338156
- [12]V Los G Encell LP McDougall MG Hartzell DD Karassina N Zimprich C Wood MG Learish R Ohana RF Urh M ACS Chem. Biol 2008 3 373 382 18533659
- [13]Long MJC Gollapalli DR Hedstrom L Chem. Biol 2012 19 629 637 22633414 PMC3361691
- [14]Heinlein CA Chang C Endocr. Rev 2004 25 276 308 15082523
- [16]Schellhammer PF Expert Opin. Pharmacother 2002 3 1313 1328 12186624
- [17]Feldman BJ Feldman D Nat. Rev. Cancer 2001 1 34 45 11900250
- [18]Scher HI Kelly WK J. Clin. Oncol 1993 11 1566 1572 7687666
- [19]Small EJ Carroll PR Urology 1994 43 408 410 7510915
- [20]Miyamoto H Rahman MM Chang C J. Cell. Biochem 2004 91 3 12 14689576
- [21]Tran C Ouk S Clegg NJ Chen Y a Watson P Arora V Wongvipat J Smith-Jones PM Yoo D Kwon A Science 2009 324 787 790 19359544 PMC2981508
- [22]Attard G Reid AH Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E J Clin Oncol 2008 26 4563 4571 18645193
- [23]Croxtall JD McKeage K Drugs 2011 71 0 363 21319872
- [24]Teutsch G Goubet F Battmann T Bonfils A Bouchoux F Cerede E Gofflo D Gaillard-Kelly M Philibert D Steroid Biochem J Mol. Biol 1994 48 111 119 8136296
- [25]Kim HR Kang HS Kim HD IUBMB Life 1999 48 429 433 10632574
- [26]McDonough H Patterson C Cell Stress Chaperones 2003 8 303 308 15115282 PMC514901
- [27]Neklesa TK Noblin DJ Kuzin A Lew S Seetharaman J Acton TB Kornhaber G Xiao R Montelione GT Tong L ACS Chem Biol 2013 8 2293 2300 23978068 PMC4113957
- [29]Egan A Dong Y Zhang H Qi Y Balk SP Sartor O Cancer Treat Rev 2014 40 426 433 24139549
- [30]Korpal M Korn JM Gao X Rakiec DP Ruddy DA Doshi S Yuan J Kovats SG Kim S Cooke VG Cancer Discov 2013 3 1030 1043 23842682
- [31]Dillard PR Lin MF Khan SA Mol Cell Endocrinol 2008 295 115 120 18782595 PMC2802176
- [32]Ishizaki F Nishiyama T Kawasaki T Miyashiro Y Hara N Takizawa I Naito M Takahashi K Sci Rep 2013 3 1528 23524847 PMC3607121
Cited by
Sorted by citations
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works
Self-citationProteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079 · see citing works
Self-citationTargeted protein degradation: mechanisms, strategies and application
Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 986 · see citing works
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674 · see citing works
Self-citationPlasticity in binding confers selectivity in ligand-induced protein degradation
Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615 · see citing works
Self-citationTargeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599 · see citing works
Self-citationTargeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 423 · see citing works
Self-citationHan, X., Wang, C., Qin, C., Xiang, W., Fernández‐Salas, E., Yang, C., Wang, M., Zhao, L., Xu, T., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01631 · Cited by 404 · see citing works
An, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363 · see citing works
Salami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349 · see citing works
Self-citationDegradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335 · see citing works
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
Riching, K. M., Mahan, S. D., Corona, C. R., McDougall, M. G., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 307 · see citing works
Small-Molecule Modulation of Protein Homeostasis.
Burslem, G., & Crews, C. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 256 · see citing works
Self-citationWaste disposal—An attractive strategy for cancer therapy
Salami, J., & Crews, C. M. (2017) · Science · doi:10.1126/science.aam7340 · Cited by 279 · see citing works
Self-citationQin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281 · see citing works
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., Xu, T., Wang, M., Yang, C., Chinnaswamy, K., Stuckey, J. A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01393 · Cited by 229 · see citing works
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 245 · see citing works
Targeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207 · see citing works
Self-citationPrey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 200 · see citing works
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Coutinho, I., Day, T. K., Tilley, W. D., & Selth, L. A. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0422 · Cited by 194 · see citing works
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176 · see citing works
Burslem, G. M., Song, J., Chen, X., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10320 · Cited by 176 · see citing works
Self-citationBardoxolone conjugation enables targeted protein degradation of BRD4
Tong, B., Luo, M., Xie, Y., Spradlin, J. N., Tallarico, J. A., McKenna, J. M., Schirle, M., Maimone, T. J., & Nomura, D. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72491-9 · Cited by 149 · see citing works
Kregel, S., Wang, C., Han, X., Xiao, L., Fernández‐Salas, E., Bawa, P., McCollum, B. L., Wilder-Romans, K., Apel, I. J., Cao, X., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2019.12.003 · Cited by 140 · see citing works
Collins, I., Wang, H., Caldwell, J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 135 · see citing works
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 126 · see citing works
Barton, V. N., D’Amato, N. C., Gordon, M. A., Christenson, J. L., ELIAS, A. D., & Richer, J. K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0232-3 · Cited by 125 · see citing works
Bivalent Ligands for Protein Degradation in Drug Discovery
Scheepstra, M., Hekking, K. F. W., Hijfte, L. V., & Folmer, R. H. A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.006 · Cited by 120 · see citing works
Targeted protein knockdown using small molecule degraders
Raina, K., & Crews, C. M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.016 · Cited by 111 · see citing works
Self-citationXie, S., Zhu, J., Li, J., Zhan, F., Yao, H., Xu, J., & Xu, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00736 · Cited by 109 · see citing works
Targeted protein degradation directly engaging lysosomes or proteasomes
Kim, J., Byun, I., Kim, D. Y., Joh, H., Kim, H. J., & Lee, M. J. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00344b · Cited by 106 · see citing works
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92 · see citing works
Targeting Nuclear Receptors with PROTAC degraders
Flanagan, J. J., & Neklesa, T. K. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110452 · Cited by 97 · see citing works
Self-citationDiscovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation
Xie, S., Zhan, F., Zhu, J., Sun, Y., Zhu, H., Liu, J., Chen, J., Zhu, Z., Yang, D., Chen, Z., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202217246 · Cited by 88 · see citing works
Li, J., Liu, T., Song, Y., Wang, M., Liu, L., Zhu, H., Li, Q., Lin, J. H., Jiang, H., Chen, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00257 · Cited by 89 · see citing works
Boc3Arg-Linked Ligands Induce Degradation by Localizing Target Proteins to the 20S Proteasome
Shi, Y., Long, M. J. C., Rosenberg, M. M., Li, S., Kobjack, A., Lessans, P., Coffey, R., & Hedstrom, L. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00656 · Cited by 84 · see citing works
Tomoshige, S., & Ishikawa, M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004746 · Cited by 84 · see citing works
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 82 · see citing works
Systematic Investigation of the Permeability of Androgen Receptor PROTACs
Scott, D. E., Rooney, T. P. C., Bayle, E. D., Mirza, T., Willems, H. M. G., Clarke, J. H., Andrews, S. P., & Skidmore, J. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00194 · Cited by 79 · see citing works
Chen, J., Qiu, M., Ma, F., Yang, L., Glass, Z., & Xu, Q. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.032 · Cited by 72 · see citing works
Bellenie, B. R., Cheung, K.-M. J., Varela, A., Pierrat, O. A., Collie, G. W., Box, G. M., Bright, M. D., Gowan, S., Hayes, A., Rodrigues, M. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02076 · Cited by 74 · see citing works
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
He, Q., Zhao, X., Wu, D., Jia, S., Liu, C., Cheng, Z., Huang, F., Chen, Y., Lu, T., & Lü, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115741 · Cited by 70 · see citing works
Monitoring and deciphering protein degradation pathways inside cells
Daniels, D. L., Riching, K. M., & Urh, M. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.12.001 · Cited by 68 · see citing works
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
Cornu, M., Lemaitre, T., Kieffer, C., & Voisin‐Chiret, A. S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104376 · Cited by 68 · see citing works
Coleman, K. G., & Crews, C. M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050430 · Cited by 66 · see citing works
Self-citationA MedChem toolbox for cereblon-directed PROTACs
Steinebach, C., Sosič, I., Lindner, S., Bricelj, A., Kohl, F., Ng, Y. L. D., Monschke, M., Wagner, K. G., Krönke, J., & Gütschow, M. (2019) · MedChemComm · doi:10.1039/c9md00185a · Cited by 66 · see citing works
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Chen, Q., Munoz, E., & Ashong, D. (2024) · Cancers · doi:10.3390/cancers16030663 · Cited by 64 · see citing works
Ito, Y., & Sadar, M. D. (2018) · Research and Reports in Urology · doi:10.2147/rru.s157116 · Cited by 63 · see citing works
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons
Wang, L., Guillen, V. S., Sharma, N., Flessa, K., Min, J., Carlson, K. E., Toy, W., Braqi, S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00106 · Cited by 59 · see citing works
TDP-43 specific reduction induced by Di-hydrophobic tags conjugated peptides
Gao, N., Huang, Y., Chu, T., Li, Q., Zhou, B. N., Chen, Y., Zhao, Y., & Li, Y. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.042 · Cited by 54 · see citing works
A critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53 · see citing works
Zhong, Y., Chi, F., Wu, H., Liu, Y., Xie, Z., Huang, W., Shi, W., & Qian, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114142 · Cited by 51 · see citing works
Hirai, K., Yamashita, H., Tomoshige, S., Mishima, Y., Niwa, T., Ohgane, K., Ishii, M., Kanamitsu, K., Ikemi, Y., Nakagawa, S., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00500 · Cited by 52 · see citing works
Tomoshige, S., Hashimoto, Y., & Ishikawa, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.035 · Cited by 52 · see citing works
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Estébanez‐Perpiñá, E., Bevan, C. L., & McEwan, I. J. (2021) · Cancers · doi:10.3390/cancers13030509 · Cited by 54 · see citing works
A sting in the tail: the N-terminal domain of the androgen receptor as a drug target
McEwan, I., & Monaghan, A. E. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.181081 · Cited by 50 · see citing works
Therapeutic Strategies to Target the Androgen Receptor
Xiang, W., & Wang, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00716 · Cited by 49 · see citing works
Go, A., Jang, J. W., Lee, W., Ha, J. D., Kim, H. J., & Nam, H. J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112635 · Cited by 48 · see citing works
Xu, F., Zhang, X., Chen, Z., He, S., Guo, J., Yu, L., Wang, Y., Hou, C., AI-furas, H., Zheng, Z., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01246 · Cited by 47 · see citing works
PROTACs bearing piperazine-containing linkers: what effect on their protonation state?
Desantis, J., Mammoli, A., Eleuteri, M., Coletti, A., Croci, F., Macchiarulo, A., & Goracci, L. (2022) · RSC Advances · doi:10.1039/d2ra03761k · Cited by 46 · see citing works
Ha, S., Luo, G., & Xiang, H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01487 · Cited by 48 · see citing works
Song, Y. Y., Park, P. M. C., Wu, L., Ray, A., Picaud, S., Li, D., Wimalasena, V. K., Du, T., Filippakopoulos, P., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0467-z · Cited by 46 · see citing works
Small-Molecule Approaches to Targeted Protein Degradation
Faust, T. B., Donovan, K. A., Yue, H., Chamberlain, P. P., & Fischer, E. S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051420-114114 · Cited by 45 · see citing works
Darwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 45 · see citing works
Degradation of Akt using protein-catalyzed capture agents
Henning, R. K., Varghese, J. O., Das, S., Nag, A., Tang, G. Y., Tang, K., Sutherland, A. M., & Heath, J. R. (2016) · Journal of Peptide Science · doi:10.1002/psc.2858 · Cited by 45 · see citing works
Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon, S., & Lee, B. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0372 · Cited by 45 · see citing works
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Jiang, L., Wang, Y., Li, Q., Tu, Z., Zhu, S., Tu, S., Zhang, Z., Ding, K., & Lu, X. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.009 · Cited by 43 · see citing works
Wang, M., Lin, R., Li, J., Suo, Y., Gao, J., Liu, L., Zhou, L., Ni, Y., Yang, Z., Zheng, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02045 · Cited by 42 · see citing works
Zeng, Y., Xiao, J., Xu, Y., Fan, W., Tian, L., Gao, Y., Chen, Y., & Hu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00828 · Cited by 42 · see citing works
Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development
Lohbeck, J., & Miller, A. K. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.048 · Cited by 41 · see citing works
Kim, T. J., Lee, Y. H., & Koo, K. C. (2021) · Biomolecules · doi:10.3390/biom11040492 · Cited by 42 · see citing works
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40 · see citing works
Self-citationRubner, S., Scharow, A., Schubert, S., & Berg, T. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201809640 · Cited by 38 · see citing works
Carborane as an Alternative Efficient Hydrophobic Tag for Protein Degradation
Asawa, Y., Nishida, K., Kawai, K., Domae, K., Ban, H. S., Kitazaki, A., Asami, H., Kohno, J., Okada, S., Tokuma, H., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00431 · Cited by 37 · see citing works
Targeted protein degradation: current molecular targets, localization, and strategies
Pliatsika, D., Blatter, C., & Riedl, R. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104178 · Cited by 37 · see citing works
Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1
Choi, S.-R., Wang, H. M., Shin, M. H., & Lim, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126407 · Cited by 34 · see citing works
Labriola, M., Atiq, S. O., Hirshman, N. A., & Bitting, R. L. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00299-9 · Cited by 33 · see citing works
Ha, S., Zhu, J., Xiang, H., & Luo, G. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109192 · Cited by 33 · see citing works
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Salama, A. K. A. A., Trkulja, M. V., Casanova, E., & Uras, I. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315440 · Cited by 32 · see citing works
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31 · see citing works
PROTACs in the Management of Prostate Cancer
Poornachandra, Y., Babalghith, A. O., Andra, V. V., & Syed, R. (2023) · Molecules · doi:10.3390/molecules28093698 · Cited by 30 · see citing works
Protein degradation: a validated therapeutic strategy with exciting prospects
Lebraud, H., & Heightman, T. D. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170030 · Cited by 29 · see citing works
The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader
Xie, H., Liang, J.-J., Wang, Y., Hu, T., Wang, J., Yang, R., Yan, J.-K., Zhang, Q., Xu, X., Liu, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112512 · Cited by 29 · see citing works
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 30 · see citing works
Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?
Powell, M., Blaskovich, M. A. T., & Hansford, K. A. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00203 · Cited by 28 · see citing works
Heitel, P. (2023) · Molecules · doi:10.3390/molecules28020690 · Cited by 27 · see citing works
Central Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 27 · see citing works
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. S. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 28 · see citing works
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 27 · see citing works
Yu, J., Zhou, P., Hu, M., Yang, L., Yan, G., Xu, R., Deng, Y., Li, X., & Chen, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111608 · Cited by 27 · see citing works
Nietzold, F., Rubner, S., & Berg, T. (2019) · Chemical Communications · doi:10.1039/c9cc07795b · Cited by 27 · see citing works
Pagoni, A., Marinelli, L., Stefano, A. D., Ciulla, M., Türkez, H., Mardinoğlu, A., Vassiliou, S., & Cacciatore, I. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111880 · Cited by 27 · see citing works
The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
Coll-Martínez, B., Delgado, A., & Crosas, B. (2020) · Molecules · doi:10.3390/molecules25245956 · Cited by 26 · see citing works
GPER blockers as Nox downregulators: A new drug class to target chronic non-communicable diseases.
Meyer, M. R., & Barton, M. (2018) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.03.019 · Cited by 27 · see citing works
Pippione, A. C., Boschi, D., Pors, K., Oliaro‐Bosso, S., & Lolli, M. L. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.44 · Cited by 27 · see citing works
Liang, J.-J., Yu, W., Yang, L., Xie, B., Qin, K.-M., Yin, Y., Yan, J., Gong, S., Liu, T.-Y., Zhou, H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114081 · Cited by 24 · see citing works
Anaya, Y. A., Barragan, M., Bracho, R. P., Shaham, S. H., Bandyopadhyay, D., George, E., Nguyen, D. D. T., & Tripathi, M. K. (2025) · Cancer · doi:10.1002/cncr.70132 · Cited by 23 · see citing works
Development of Agonist-Based PROTACs Targeting Liver X Receptor
Xu, H., Ohoka, N., Yokoo, H., Nemoto, K., Ohtsuki, T., Matsufuji, H., Naito, M., Inoué, T., Tsuji, G., & Demizu, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.674967 · Cited by 23 · see citing works
Rubner, S., Schubert, S., & Berg, T. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00080a · Cited by 22 · see citing works
Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 22 · see citing works
- Authors
- Gustafson, J. L., Neklesa, T. K., Cox, C. S., Roth, A. G., Buckley, D. L., Tae, H. S., Sundberg, T. B., Stagg, D. B., Hines, J., McDonnell, D. P., Norris, J. D., & Crews, C. M.
- Affiliations
- Yale University (US)
- Duke University (US)
- Corresponding author
- Crews, Craig M.
- ORCID
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2015-06-17
- Volume
- 54
- Issue
- 33
- Pages
- 9659-9662
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- PMC
- PMC4547777
- OpenAlex
- W2117170436
- Cited by
- 206
- References
- 33
- Citations by year
- 2026: 20 · 2025: 23 · 2024: 17 · 2023: 22 · 2022: 22 · 2021: 15 · 2020: 23 · 2019: 18 · 2018: 17 · 2017: 16 · 2016: 11 · 2015: 1 · 2014: 1
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA139818)
- National Institute of General Medical Sciences (T32GM067543, F32GM10052101, F32GM100521)
- National Institute of Allergy and Infectious Diseases (R01AI084140)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Keywords
- androgen receptor, protein degradation, enzalutamide resistance, androgen receptor antagonists, prostate cancer, androgen receptor agonists, small-molecule ligands, drug resistance
- MeSH terms
- Antineoplastic Agents, Benzamides, Humans, Male, Nitriles, Phenylthiohydantoin, Prostate, Prostatic Neoplasms, Receptors, Androgen, Point Mutation, Drug Resistance, Neoplasm, Cell Line, Tumor, Cell Proliferation, Small Molecule Libraries, Hydrophobic and Hydrophilic Interactions, Androgen Receptor Antagonists, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
